<DOC>
	<DOCNO>NCT02225106</DOCNO>
	<brief_summary>OBJECTIVES : Deficits memory , attention , cognitive , executive function common disability traumatic brain injury ( TBI ) . Dopamine ( DA ) neurotransmission implicate neural function dopaminergic pathway recognize frequently disrupt TBI . One widely use DAergic drug methylphenidate ( Ritalin ) . Methylphenidate increase synaptic DA level bind presynaptic dopamine transporter ( DAT ) block re-uptake . PET methylphenidate challenge measure tonic DA release provide valuable insight molecular basis attention-deficit hyperactivity disorder ( ADHD ) addiction , well practical information regard likely effectiveness therapy ( 1 ) . The objective study use PET image [ 11C ] -raclopride , D2/D3 receptor ligand , administer methylphenidate , measure endogenous DA release patient experience problem cognition , attention executive function chronic stage TBI . In addition , use TMS test short intracortical inhibition , gamma-aminobutyric acid receptor A ( GABAA ) - mediate phenomenon , partial DA control , measure dopaminergic activity methylphenidate . STUDY POPULATION : Males female ( n=30 ) , age 18 55 year chronic stage TBI experience deficit neuropsychological function TBIs incur 6 month injury , recruit military treatment facility civilian clinic present clinical management TBI postconcussive symptom . DESIGN : 1 . Study participant evaluate use brain MRI , psychometric measure adapt TBI Common Data Elements , attention test information detail injury experience post-concussive symptom record . Transcranial magnetic stimulation ( TMS ) placebo methylphenidate ( 60 mg mouth ) challenge perform predict stimulant response . 2 . Subjects study [ 11C ] -raclopride PET two imaging session . One session administration placebo methylphenidate , 60 mg mouth . Both placebo methylphenidate give 60 minute prior injection [ 11C ] -raclopride allow peak uptake methylphenidate brain . The bind potential [ 11C ] -raclopride relative non-displaceable reference region ( cerebellum ) , BPND , use measure D2/D3 receptor availability . The difference BPND methylphenidate placebo ( BPND ) use measure tonic DA release . 3 . Subjects treat oral methylphenidate , use force titration dose 30 mg give twice daily 4 week . At point , neuropsychologic test repeat . OUTCOME MEASURES : The primary outcome change information process speed neuropsychologic testing</brief_summary>
	<brief_title>Dopamine Receptor Imaging Predict Response Stimulant Therapy Chronic TBI</brief_title>
	<detailed_description>OBJECTIVES : Deficits memory , attention , cognitive , executive function common disability traumatic brain injury ( TBI ) . Dopamine ( DA ) neurotransmission implicate neural function dopaminergic pathway recognize frequently disrupt TBI . One widely use DAergic drug methylphenidate ( Ritalin ) . Methylphenidate increase synaptic DA level bind presynaptic dopamine transporter ( DAT ) block re-uptake . PET methylphenidate challenge measure tonic DA release provide valuable insight molecular basis attention-deficit hyperactivity disorder ( ADHD ) addiction , well practical information regard likely effectiveness therapy ( 1 ) . The objective study use PET image [ 11C ] -raclopride , D2/D3 receptor ligand , administer methylphenidate , measure endogenous DA release patient experience problem cognition , attention executive function chronic stage TBI . In addition , use TMS test short intracortical inhibition , gamma-aminobutyric acid receptor A ( GABAA ) - mediate phenomenon , partial DA control , measure dopaminergic activity methylphenidate . STUDY POPULATION : Males female ( n=30 ) , age 18 55 year chronic stage TBI experience deficit neuropsychological function TBIs incur 6 month injury , recruit military treatment facility civilian clinic present clinical management TBI postconcussive symptom . DESIGN : 1 . Study participant evaluate use brain MRI , psychometric measure adapt TBI Common Data Elements , attention test information detail injury experience post-concussive symptom record . Transcranial magnetic stimulation ( TMS ) placebo methylphenidate ( 60 mg mouth ) challenge perform predict stimulant response . 2 . Subjects study [ 11C ] -raclopride PET two imaging session . One session administration placebo methylphenidate , 60 mg mouth . Both placebo methylphenidate give 60 minute prior injection [ 11C ] -raclopride allow peak uptake methylphenidate brain . The bind potential [ 11C ] -raclopride relative non-displaceable reference region ( cerebellum ) , BPND , use measure D2/D3 receptor availability . The difference BPND methylphenidate placebo ( BPND ) use measure tonic DA release . 3 . Subjects treat oral methylphenidate , use force titration dose 30 mg give twice daily 4 week . At point , neuropsychologic test repeat . OUTCOME MEASURES : The primary outcome change information process speed neuropsychologic testing</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<criteria>INCLUSION : To include protocol , study participant must meet following criterion : 1 . Age 18 55 year , inclusive 2 . A history sustain moderate severe TBI &gt; 6 month prior enrollment . Evidence one follow 3 criterion : 1 . GCS 3 12 ( GCS obtain Emergency Room note medical record ) 2 . Posttraumatic amnesia &gt; 24 hour 3 . TBIrelated abnormality neuroimaging ( either CT MRI ) . ( Some miss information initial injury [ i.e. , documentation initial GCS ] necessarily exclusionary bulk available history indicate patient suffer TBI meet inclusion criterion ) 3 . Persistent postconcussive symptom , accord DSMIV Research Criteria PostConcussional Disorder , include : 1 . Difficulty attention memory . 2 . One follow symptom , start shortly trauma persist least three month : ) Fatigability ii ) Disordered sleep iii ) Changes personality iv ) Apathy lack spontaneity c ) Symptoms criterion ( ) ( b ) must onset trauma , significant worsen preexist symptom trauma . ) Disturbance symptoms cause significant impairment social occupational functioning represent significant decline previous level functioning . 4 . Ability read , write , speak English 5 . Ability give inform consent . EXCLUSION : 1 . Evidence penetrate brain injury . 2 . Contraindication methylphenidate therapy : 1 . Known glaucoma ( consistently raise intraocular pressure without associate optic nerve damage ) 2 . Motor tics family history Tourette syndrome ( diagnose presence multiple motor one vocal tic period year , three consecutive ticfree month ) 3 . Known hypersensitivity methylphenidate ( hive , difficulty breathing , swell face , lip , tongue , throat ) . 4 . Known severe anxiety restlessness prevents day day activity . 5 . Known preexist hypertension , heart failure , myocardial infarction , ventricular arrhythmia . 6 . Known preexist psychosis , bipolar illness . 7 . History seizure , interictal epileptiform discharge ( IEDs ) EEG absence seizure . 8 . Known peripheral vasculopathy , include Raynaud phenomenon . 9 . History drug dependence alcoholism . 10 . Concomitant treatment coumadin anticoagulant , anticonvulsant ( e.g. , phenobarbital , phenytoin , primidone ) , tricyclic drug ( e.g. , imipramine , clomipramine , desipramine ) . 11 . Concomitant therapy monoamine oxidase inhibitor ( Marplan ( isocarboxazid ) , Nardil ( phenelzine ) , Emsam ( selegiline ) , Parnate ( tranylcypromine ) 12 . Concomitant treatment blood pressure medication ( high low blood pressure ) . 13 . Pregnancy 14 . Breastfeeding 3 . History evidence disable preexist coexist disable neurologic psychiatric disorder related TBI , : 1 . Multiple sclerosis , pre coexist 2 . Stroke ( stroke time TBI ) 3 . Preexisting disable developmental disorder 4 . Preexisting epilepsy 5 . Preexisting major depressive disorder , aggressive behavior , hostility 6 . Preexisting schizophrenia 4 . Contraindication MRI scan 1 . Ferromagnetic metal cranial cavity eye , e.g. , aneurysm clip , implanted neural stimulator , cochlear implant , ocular foreign body 2 . Implanted cardiac pacemaker autodefibrillator pump 3 . Nonremovable body pierce 4 . Claustrophobia 5 . Inability lie supine two hour 5 . Contraindication TMS , metal cranial cavity implant electronic hardware . 6 . Current participation interventional clinical trial 7 . Nonadherence use effective method contraception females able become pregnant time enrollment study 2 week completion study drug . 8 . Present history alcohol substance abuse disorder determine ( DSMIV ) . 9 . Body mass index ( BMI ) &gt; 40</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 12, 2016</verification_date>
	<keyword>Dopamine Receptors</keyword>
	<keyword>Methylphenidate</keyword>
	<keyword>Traumatic Brain Injury</keyword>
	<keyword>C-11 Raclopride</keyword>
	<keyword>Dopamine Release</keyword>
</DOC>